Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Trutakna Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentEmpire BluecrossPolicy CC-0306

    Trutakna (atacicept-vymj) coverage for primary immunoglobulin A nephropathy

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0306 alerts

    Get alerted when Policy CC-0306 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity review for Trutakna (atacicept-vymj) used to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. It applies to providers requesting coverage under a member's medical benefit or clinical review process.

    Policy Summary
    PayerEmpire Bluecross
    PolicyTrutakna (atacicept-vymj) coverage for primary IgAN
    Policy CodePolicy CC-0306
    Change TypeNew clinical criteria and quantity limit
    Effective DateJul 28, 2026
    Last ReviewJul 13, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with kidney-biopsy verification and documentation of maximally tolerated ACE inhibitor or ARB therapy and planned concurrent background therapy.
    SourceLink
    POLICY UPDATE CHANGES

    New clinical criteria and a quantity limit were added for Trutakna.

    HCPCS codes C9399 and J3590 and ICD-10-CM code range N02.B1-N02.B9 were added for Trutakna and recurrent or persistent IgA nephropathy.

    Documentation requirements were added for biopsy verification and concurrent background therapy.

    6 monthsInitial approval
    1 yearContinuation approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥30
    Minimum eGFR
    ≥1 g/g or ≥1 g/dayProteinuria threshold
    4/28 daysQuantity limit
    3Excluded combinations

    Coverage Criteria

    Initial Therapy Criteria

    Initial requests may be approved when all of the following are met:

    Initial therapy

    • Diagnosis and prior therapy: The individual has primary IgAN verified by kidney biopsy and has had a trial of maximally tolerated ACE inhibitor or ARB therapy unless contraindicated or not tolerated.
    • Proteinuria: ONE of

      • UPCR criterion: Urine protein-to-creatinine ratio (UPCR) is at least 1 g/g.≥ 1 g/g
      • Urine protein criterion: Urine protein is at least 1 g/day.≥ 1 g/day
    • Kidney function: eGFR is at least 30 mL/min/1.73 m².≥ 30 mL/min/1.73 m²
    • Concomitant therapy: The individual will take Trutakna in combination with an ACE inhibitor, ARB, or Filspari (sparsentan) unless contraindicated or not tolerated.

      KDIGO 2025

    Continuation Therapy Criteria

    Continuation requests may be approved when all of the following are met:

    Continuation therapy

    • Response: There is a clinically significant reduction in proteinuria.
    • Concomitant therapy: The individual will take Trutakna in combination with an ACE inhibitor, ARB, or Filspari (sparsentan) unless contraindicated or not tolerated.

      KDIGO 2025

    Trutakna must not be used in combination with Tarpeyo (budesonide delayed release), Fabhalta (iptacopan), or Voyxact (sibeprenlimab-szsi). Requests involving any of these combinations may not be approved.

    Coding Information

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Trutakna (atacicept-vymj)]
    J3590Unclassified biologics [when specified as Trutakna (atacicept-vymj)]
    ICD-10 DiagnosisICD-10
    N02.B1-N02.B9Recurrent and persistent immunoglobulin A nephropathy
    Urine protein-to-creatinine ratio
    Required threshold≥ 1 g/g
    MeasureUrine protein-to-creatinine ratio (UPCR)
    Initial therapy useProteinuria may meet the UPCR threshold as one of the qualifying criteria for initial Trutakna therapy.
    Urine protein
    Required threshold≥ 1 g/day
    MeasureUrine protein
    Initial therapy use

    Provider Requirements and Approval Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required when Trutakna is reviewed under the member’s medical-benefit coverage or is otherwise subject to clinical review. Requests must satisfy all applicable medical-necessity criteria for the intended or prescribed use.

    Step Therapy

    RAS-Inhibitor Background Therapy

    Before initial approval, document a trial of maximally tolerated ACE inhibitor or ARB therapy unless contraindicated or not tolerated. Trutakna must also be planned in combination with an ACE inhibitor, ARB, or Filspari (sparsentan), unless combination therapy is contraindicated or not tolerated, consistent with KDIGO 2025.

    Documentation Required

    Kidney Biopsy Verification

    Clinical Background

    Trutakna (atacicept-vymj) is a BLyS-specific inhibitor and APRIL blocker approved by the FDA to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Its accelerated approval was based on reduction of proteinuria, with continued approval potentially contingent on confirmation of clinical benefit.

    Key Definitions

    Primary immunoglobulin A nephropathy (IgAN)
    DiseasePrimary immunoglobulin A nephropathy (IgAN)
    DefinitionA kidney disease involving immunoglobulin A nephropathy.
    Diagnosis requirementDiagnosis must be verified with a kidney biopsy because there are no validated serum or urine biomarkers.
    UPCR
    Full termUrine protein-to-creatinine ratio
    DefinitionA measure of urine protein relative to urine creatinine.
    UnitsGrams of protein per gram of creatinine (g/g)

    Trutakna Initial Therapy

    Trutakna Initial Therapy

    Initial requests may be approved if all of the following criteria are met:

    Trutakna initial therapy

    • Diagnosis and prior therapy: The individual has a diagnosis of primary immunoglobulin A nephropathy (IgAN), the diagnosis has been verified with kidney biopsy, and the individual has had a trial of maximally tolerated ACE inhibitor or ARB therapy unless contraindicated or not tolerated.
    • ONE of the following proteinuria criteria

      • UPCR: Urine protein-to-creatinine ratio (UPCR) is at least 1 g/g.≥ 1 g/g
      • Urine protein is at least 1 g/day.

    Trutakna Continuation

    Trutakna Continuation

    Continuation requests may be approved if all of the following criteria are met:

    Trutakna continuation

    • Response: There is a clinically significant reduction in proteinuria.
    • Concomitant therapy: Documentation is provided that the individual will take Trutakna in combination with an ACE inhibitor, ARB, or Filspari (sparsentan) unless contraindicated or not tolerated.

      KDIGO 2025

    Required Background Therapy

    StepTherapyPrior therapy requirementConcurrent therapy requirement
    1Trutakna (atacicept-vymj)Use after or with a trial of maximally tolerated ACE inhibitor or ARB therapy, unless contraindicated or not tolerated.Trutakna must be taken with an ACE inhibitor, ARB, or Filspari (sparsentan), unless contraindicated or not tolerated.

    Dispensing Limits

    Trutakna quantity limit
    ProductTrutakna (atacicept-vymj) 150 mg/mL, quantity 1
    Quantity limit4 autoinjectors
    Limit periodPer 28 days
    Trutakna quantity limit
    ProductTrutakna (atacicept-vymj) 150 mg/mL, quantity 2
    Quantity limit4 autoinjectors
    Limit periodPer 28 days
    Policy Summary
    PayerEmpire Bluecross
    PolicyTrutakna (atacicept-vymj) coverage for primary IgAN
    Policy CodePolicy CC-0306
    Change TypeNew clinical criteria and quantity limit
    Effective DateJul 28, 2026
    Last ReviewJul 13, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with kidney-biopsy verification and documentation of maximally tolerated ACE inhibitor or ARB therapy and planned concurrent background therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Requirements and Approval RisksClinical BackgroundKey DefinitionsTrutakna Initial TherapyTrutakna ContinuationRequired Background TherapyDispensing Limits
    Proteinuria may meet the urine protein threshold as one of the qualifying criteria for initial Trutakna therapy.
    eGFR
    Minimum threshold≥ 30 mL/min/1.73 m²
    MeasureEstimated glomerular filtration rate (eGFR)
    Initial therapy useThe individual must have an eGFR meeting this minimum threshold.

    For an initial request, provide documentation confirming that the diagnosis of primary immunoglobulin A nephropathy (IgAN) has been verified by kidney biopsy.

    Documentation Required

    Background Therapy Documentation

    Document both the maximally tolerated ACE inhibitor or ARB trial and the planned concurrent background therapy. The concurrent regimen must include an ACE inhibitor, ARB, or Filspari (sparsentan), unless contraindicated or not tolerated.

    Documentation Required

    Continuation Documentation

    For continuation approval, document a clinically significant reduction in proteinuria and the planned concurrent use of an ACE inhibitor, ARB, or Filspari (sparsentan), unless contraindicated or not tolerated.

    Denial Risk

    Prohibited Concomitant Therapy

    Trutakna may not be used in combination with Tarpeyo (budesonide delayed release), Fabhalta (iptacopan), or Voyxact (sibeprenlimab-szsi).

    Denial Risk

    Failure to Meet Initial Criteria

    Initial requests may be denied when the required diagnosis or kidney-biopsy verification is not documented, the maximally tolerated ACE inhibitor or ARB trial is absent without a documented contraindication or intolerance, or the remaining initial criteria are not met.

    • Primary IgAN diagnosis must be documented.
    • Proteinuria must meet at least one threshold: UPCR ≥ 1 g/g or urine protein ≥ 1 g/day.
    • eGFR must be ≥ 30 mL/min/1.73 m².
    • Planned combination therapy with an ACE inhibitor, ARB, or Filspari is required unless contraindicated or not tolerated.
    • Initial approval duration: 6 months.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation requests may be denied when clinically significant proteinuria reduction is not documented or when required concurrent therapy with an ACE inhibitor, ARB, or Filspari is not planned, unless contraindicated or not tolerated.

    • Continuation approval duration: 1 year.
    • Combination with Tarpeyo, Fabhalta, or Voyxact is not permitted.
    eGFR
    Full termEstimated glomerular filtration rate
    DefinitionA measure used to assess kidney filtration function.
    UnitsmL/min/1.73 m²
    RAS inhibition
    Therapy classRenin-angiotensin system (RAS) inhibition
    Accepted agentsAn angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
    Additional accepted therapyFilspari (sparsentan) is identified as an acceptable concomitant therapy.
    ≥ 1 g/day
  1. Kidney function: eGFR is at least 30 mL/min/1.73 m².≥ 30 mL/min/1.73 m²
  2. Concomitant therapy: Documentation is provided that the individual will take Trutakna in combination with an ACE inhibitor, ARB, or Filspari (sparsentan) unless contraindicated or not tolerated.

    KDIGO 2025